2019-01-19| Asia-Pacific

2019 Asia-Pacific Extracellular Vesicles Conference Made the World-leading Experts Gathered in Taipei

by GeneOnline
Share To

2019 Asia-Pacific Extracellular Vesicles Conference is debuting on 1/19-1/20 at National Taiwan University (NTU) College of Medicine. This conference is co-organized by Taiwan Society for Extracellular Vesicles (TSEV), Taiwan Breast Cancer Foundation, Taiwan Proteomics Society, International Center for Wound Repair and Regeneration, National Cheng Kung University, NTU Center of Biotechnology, NTU Centers of Genomic and Precision Medicine, NTU Centers of Genomic and Systems Biology, with 300 experts, scholars mostly from Asia Pacific region, and more than 10 companies exhibit together.

NTU Professor Tang-Long Shen, the president of TSEV, expressed that the extracellular vesicles (EVs) research is booming, but in Taiwan’s conference there are very few related topics. Therefore, the purpose of TSEV is to advocate and educate EV researches, as well as to provide international networking for local academics, medicals, and industries through the society.

Dr. Ming-Jer Tang, the chairman of the conference, believes that the research on EVs has progressed rapidly, hoping that through this conference would promote the scholars and experts to exchange ideas and provide the opportunities for international collaboration, so that Taiwan’s foundation of academic research will have more room for development.

This 2 day conference will focus on six major topics, from EV-based therapeutics, cancer diagnosis, detection and imaging, cancer proteomics/genomics, cancer biology to cancer metastasis. With international speakers including Professor Takahiro Ochiya of National Cancer Centre Japan, Dr. Sai Kiang Lim from A*STAR, Dr. Andrew Hill from La Trobe University, Dr. Lei Zheng from Southern Medical University, Dr. Andreas Möller from QIMR Berghofer, Dr. L. James Lee from Ohio State University, Dr. Hideo Tahara from Hiroshima University and Dr. Yong Song Gho from Pohang University to cover the topics of current EV researches.

Dr. King-Jen Chang, the chairman of Taiwan Breast Cancer Foundation, as a clinician, he is looking forward to this conference. He said that the EV-related research has the opportunity to be widely used in the diagnosis and treatment on cancer. With the liquid biopsy analysis, the efficiency of detecting diseases will be more immediate than the many of the existing detection for diseases, such as the symptom appearance, optical inspection, or biopsy. These characteristics made the clinical testing easier and more accurate, which will highly improve cancer care.

Andrew Hill, the president of International Society for Extracellular Vesicles (ISEV) is sharing the most current trends of EV research in this event, including the new MISEV guideline that were released by ISEV in December 2018. This publication features nearly 400 authors from the EV community, together to develop guideline on EV research. This is going to help shape the future of the research field. Also, coming up on April 24-28. This year’s International Society for Extracelluar Vesicles Annual Meeting will be held in Asia-Pacific for the first time at the Miyakomesse in Kyoto, Japan. Dr. Hill said the ISEV is looking forward to see many professionals from this region to attend as well as the international speakers and colleagues. It will be very exciting to see many advancement in the meeting.


© All rights reserved. Collaborate with us:
Related Post
AstraZeneca, Ionis’ ATTR Drug Edges Closer to US Approval With Latest Trial Win
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
These Companies Are Harnessing Oncolytic Viruses to Target Cancer
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
Breakthrough Zebrafish Genome Database Now Available
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
BIO Asia–Taiwan 2022
Online and on-side
ESMO 2022 Exhibition
Online and on-side
RESI Boston
CSCO Educational Book 2022
Human Gene Therapy Conference
Scroll to Top